Cost‐efficacy and pharmacoeconomics of psoriatic patients in Japan: Analysis from a single outpatient clinic

Abstract

Compared with topical corticosteroids, topical combined active vitamin D3/corticosteroids and especially biologics are more expensive despite their marked efficacy in the treatment of psoriasis. The aim of the present study is to evaluate total costs as well as costs versus efficacy of various psoriasis treatments under the current Japanese health‐care insurance system. A prospective study was performed from the database of a single clinic located in Hokkaido Prefecture. Cost and quality of life of psoriatic patients were evaluated in a prospective manner during a total of 12 months from March 2017 until June 2018. Quality‐adjusted life year (QALY) of biologics was the highest among all treatments. Among the topical treatments, the cost versus efficacy of combined active vitamin D3/corticosteroid was lowest (¥10 557/1 Psoriasis Area and Severity Index). Furthermore, incremental cost‐effectiveness ratio (ICER) of combined active vitamin D3/corticosteroid was ¥1 024 031/QALY when compared with topical corticosteroid treatment alone. The topical combined active vitamin D3/corticosteroid treatment showed the best cost‐efficacy in terms of medical economic burden.

Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis

“…Males are twice as likely to be affected than females [112,113]. The cosmetic disfigurement associated with psoriasis profoundly impairs the patients’ quality of life, treatment satisfaction and adherence, and socioeconomic stability [114,115]. The autoimmune nature of psoriasis is exemplified by its high comorbidity with psoriatic arthritis [110,116,117,118] and other autoimmune diseases including autoimmune bullous diseases [119,120,121,122,123,124].…”

Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis

“…[30][31][32] Due to a profound cosmetic burden, patients' quality of life, treatment satisfaction and adherence, and social activities are deteriorated by psoriasis. 30,33 Psoriasis is considered as an autoimmune or autoinflammatory disease with high rate of comorbidities, including psoriatic arthritis 30,[34][35][36] and other autoimmune diseases such as autoimmune bullous diseases. 32,[37][38][39][40] Comorbid conditions of psoriasis further comprise cardiovascular diseases, metabolic diseases and renal disorders, collectively called the inflammatory skin march.…”

Interleukin-17A and Keratinocytes in Psoriasis

“…Males are twice as likely as females to be affected [3,4]. As desquamative erythema can affect any skin site, psoriasis profoundly impairs the patients' quality of life, treatment satisfaction and adherence, and socioeconomic stability [5][6][7]. The skin lesion usually appears on the sites with frequent trauma such as elbows and knees [8,9].…”